Remepy is Pioneering Hybrid Drugs™. 
We believe that in the future, software applications will become an integral part of treatments offered by Pharma companies in the form of Hybrid Drugs™. These will include both a software component and a traditional drug component - influencing patients via Hybrid Mechanisms of Action™.

Remepy’s Digital Molecules™ are designed to be the software components within Hybrid Drugs™. They are based on digital interventions and treatment protocols that are tailored to each medical condition and its corresponding drug. 
The Digital Molecules™ enhance brain functions that balance the patient's neuro-endocrine and neuro-immunological systems and boost brain neuroplasticity, in order to optimize drug performance. 

Remepy partners with pharma companies to bring Hybrid Drugs™ to market that will combine  Remepy’s Digital Molecule™ and traditional drug components.

Pharmaceutical

Remepy

Or Shoval

Sheila Oren

Michal Tsur

Lior Benderski

Shai Elrich

Shahar Shelly

Nira Saporta

Jonathan Amit - Kanarek

Amir Amedi

Leadership Team

Medical and Clinical Team

Engineering Team

Teams at Remepy

Leadership Team

Medical and Clinical Team

Engineering Team